With over two decades of medical experience, Dr. Roebuck is an ENT specialist, a board-certified otolaryngologist, a highly trained otologist and has been recognized for his academic achievements and a recipient of multiple professional awards.
Dr. Roebuck is the owner and Medical Director of The Med Spa, a modern innovative facility offering a multitude of anti-aging, rejuvenation, hydration and wellness services.
Hydreight started trading under the symbol ‘NURS’ on the TSX Venture Exchange at market open on December 1, 2022.
Hydreight’s licenses, medical director offering, and technology allow med-spas as well as healthcare professionals to be able to offer wellness services, testing, medical and medispa treatments all in the comfort of home or at any other location of the customer’s choice.
Hydreight recently reported adjusted revenue (see Use of Non-GAAP Financial Measures) for the nine months ended September 30, 2022 of $5,612,587 compared to $1,640,001 for the nine months ended September 30, 2021.
VANCOUVER, British Columbia, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Hydreight Technologies Inc. (formerly Perihelion Capital Ltd.) ("Hydreight" or the "Company") (TSXV: NURS) is pleased to announce that it has appointed Dr. Jeremy Roebuck to the Board of Advisors, effective December 12, 2022.
Hydreight CEO Shane Madden said, “We couldn't be more excited and honored to welcome Dr. Roebuck to our Board of Advisors. The wealth of knowledge, experience and connections he brings to the company cannot be overstated. At a time when we are focused on driving revenue and profitability, an industry veteran like Dr. Roebuck will have an immediate impact on our business. His network and experience in the precise space we are in is second-to-none. Dr. Roebuck is an excellent addition to the team who I’m excited to continue building the future of our Company with.”
Dr. Jeremy Roebuck is an ENT specialist who was born and raised in Southeast Texas. He received his undergrad from Lamar University and his doctorate from the University of Texas Medical School in Houston. He completed his residency in general surgery and otolaryngology in Houston, and his fellowship in neurotology at the Minnesota Ear, Head and Neck Clinic in Minneapolis. He is a board-certified otolaryngologist and is also a highly trained otologist. He has also been recognized for his academic achievements and a recipient of multiple professional awards.
Dr. Roebuck has been in private practice for 15 years. He has dedicated his practice to the entire breadth of pediatric and adult ENT diseases with comprehensive medical and surgical care. He has special interest in sinonasal disease, minimally invasive sinus surgery, sinuplasty, environmental allergies, hearing and balance disorders, chronic ear disease and implanted hearing devices. He is currently staffed at Christus St. Elizabeth Hospital and Baptist Hospital of Southeast Texas.
Dr. Roebuck is also the owner and Medical Director of The Med Spa. The Med Spa is a modern innovative facility offering a multitude of anti-aging, rejuvenation, hydration and wellness services. This includes anti-aging aesthetic injectable such as Botox/Dysport, Dermal Fillers, Kybella, Juvederm and PRP, customized facials, body sculpting, laser and light therapy, micro needling, microblading and top of the line skin care products and much more. It also offers specialized IV hydration for illness recovery, boosting immune system, detoxification, cell rejuvenation, metabolism/weight maintenance, energy levels, performance enhancement/recovery, migraine/pain relief, general hydration and overall wellness.
“I’m thrilled to be on the board of a company on the cutting edge of health and wellness. Hydreight makes the benefits of medicine more accessible to patients while also allowing health care providers an avenue to provide improved direct care. Essentially, with Hydreight the technology space has merged with health to create a new model for business that I am proud to be a part of for years to come. I’m excited to merge my experience in medicine with the advanced technology that Hydreight brings to the marketplace,” said Dr. Jeremy Roebuck.
Hydreight recently announced that it has filed its consolidated condensed interim financial statements for the three and nine months ended September 30, 2022. To read click here
Additional information regarding Hydreight can be viewed on its website at www.hydreight.com.
On behalf of the Board of Directors
Director and Chief Executive Officer
Hydreight Technologies Inc.
Telephone: (480) 790 6886
For further information about Hydreight, please contact:
Contact – Abbey Vogt
Telephone: (480) 790 6886
Marketing and Media Contact- Jessica Friedman
Telephone: (480) 790 6886
Hydreight’s business was founded in April, 2018, in the State of Nevada, United States to fill an ever evolving void between patients, healthcare professionals and service advisors, and bridge the gap between the corporate practice of medicine, legal compliance and customer convenience. Hydreight’s licenses, medical director offering, and technology allow med-spas as well as healthcare professionals, such as nurses, to be able to offer their services, which includes IV drip, Botox, COVID-19 testing, and other medical and medispa treatments all in the comfort of home or at any other location of the customer’s choice (such as the office, hotels, or other locations outside of hospitals and medical clinics). Hydreight aims to be a one stop shop for service providers to monetize their credentials outside of a fixed setting such as a hospital or medical clinic.
Hydreight currently offers its mobile and telehealth medical services in 42 U.S. states and has established key relationships and supply network chains with major vendors including: Medline, Mckesson, Allergan (Botox), Galderma and numerous pharmacies. Hydreight aims to empower pharmacies to provide their products to service providers in a direct and easily accessible manner.
On February 10, 2021, IV Hydreight Inc. was acquired by Victory Square Technologies Inc. (“VST”) (CSE:VST) (OTC:VSQTF). Pursuant to the Company’s transaction with IV Hydreight Inc., VST sold its interest in IV Hydreight Inc. and now owns approximately 73.72% of the issued and outstanding common shares of the Company (the “Common Shares”).
Hydreight had secured master vendor contracts with strategic 503B compounding pharmacies to facilitate the offering of its platform in all 50 states of the United States. Hydreight is acting as an Uber for nurses that can offer their services on a part time or full time basis directly to patients, allowing consumers to book appointments online, in person or through telehealth platforms with certified and registered health professionals.
In 2021 Hydreight welcomed approximately 101 new business partners, and in 2022, Hydreight has obtained approximately 537 new business partners as of the end of October, and expects to obtain an aggregate of 725 new business partners by the end of the year. (an approx. 606% Growth Rate in YOY new business partner sign-ups).
Neither TSXV nor its Regulation Services Provider (as that term is defined in policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release. This press release does not constitute an offer of securities for sale in the United States. The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and such securities may not be offered or sold within the United States absent U.S. registration or an applicable exemption from U.S. registration requirements.
Use of Non-GAAP Financial Measures:
This release contains references to non-GAAP financial measures Adjusted Revenue and Adjusted Gross Margin. The Company defines Adjusted Revenue as gross cash income before adjustment for the deferred portion of business partner contract revenue and gross receipts from Hydreight App service sales. The Company defines Adjusted Gross Margin as Adjusted Revenue less business partner payouts on App service sales and pharmacy cost of sales. There is no comparable GAAP financial measure presented in IV Hydreight Inc. and Hydreight Technologies Inc condensed consolidated interim financial statements and thus no applicable quantitative reconciliation for such non-GAAP financial measure. The Company believes that the measure provides information useful to its shareholders in understanding the Company’s performance, and may assist in the evaluation of the Company’s business relative to that of its peers. This data is furnished to provide additional information and does not have any standardized meaning prescribed by GAAP. Accordingly, it should not be considered in isolation or as a substitute for measures of performance prepared in accordance with GAAP, and is not necessarily indicative of other metrics presented in accordance with GAAP.
Cautionary Note Regarding Forward-Looking Information
This press release contains statements which constitute “forward-looking information” within the meaning of applicable securities laws, including statements regarding the plans, intentions, beliefs and current expectations of the Company with respect to future business activities and operating performance. Forward-looking information is often identified by the words “may”, “would”, “could”, “should”, “will”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “expect” or similar expressions and includes information regarding: expectations regarding the number of new business partners of Hydreight by the end of 2022.
Investors are cautioned that forward-looking information is not based on historical facts but instead reflect the Company’s management’s expectations, estimates or projections concerning future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although the Company believes that the expectations reflected in such forward-looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements of the Company. Among the key factors that could cause actual results to differ materially from those projected in the forward-looking information are the following: the ability to obtain requisite regulatory and other approvals with respect to the business operated by the Company and/or the potential impact of the listing of the Company’s shares on the TSXV on relationships, including with regulatory bodies, employees, suppliers, customers and competitors; changes in general economic, business and political conditions, including changes in the financial markets; changes in applicable laws; compliance with extensive government regulation; and the diversion of management time as a result of being a publicly listed entity. This forward-looking information may be affected by risks and uncertainties in the business of the Company and market conditions.
Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The Company does not intend, and does not assume any obligation, to update this forward-looking information except as otherwise required by applicable law.